Inactive

The OTSG is acquiring Panther Fusion SARS-CoV-2 assays, Aptima SARS-CoV-2 assays, Multiplex test kits and associated reagents and consumables in order to conduct COVID-19 testing on the Hologic Panthe... The OTSG is acquiring Panther Fusion SARS-CoV-2 assays, Aptima SARS-CoV-2 assays, Multiplex test kits and associated reagents and consumables in order to conduct COVID-19 testing on the Hologic Panther and Panther Fusion systems. The Panther Fusion SARS-CoV-2 test kits are qualitative tests for the detection of nucleic acid from SARS-CoV-2 isolated and purified from NP, nasal, mid-turbinate and OP swab specimens, nasopharyngeal wash/aspirate or nasal aspirates obtained from individuals who meet COVID-19 clinical and/or epidemiological criteria; and from individuals without symptoms or other reasons to suspect COVID-19 infection. The Panther Fusion and Panther Systems are integrated nucleic acid testing systems that fully automate all steps necessary to perform various Panther Fusion and Panther assays from sample processing through amplification, detection, and data reduction. The Panther Fusion SARS-CoV-2 testing capability on the Panther Fusion System primarily consists of Panther Fusion SARS-CoV-2 PPR Mix; Open Access Cartridges, RNA/DNA ENZ; and additional vendor specific reagents and consumables required to perform the SARS-CoV-2 test. Aptima SARS-CoV-2 testing capability on the Panther and Panther Fusion primarily consists of Aptima SARS-CoV-2 assay kit, Solid Cap Specimen Lysis Tubes, and additional vendor specific reagents and consumables required to perform the SARS-CoV-2 test. The multiplex test kit is currently under production and capable of simultaneous detection of both influenza A & B and COVID-19.